ASB3

Across TCGA pan-cancer cohorts, ASB3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ASB3 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ASB3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ASB3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

HNSC, PDAC, and GBM are the cancer types where ASB3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.949	0.153	.038	24	view →
PDAC	DFS	Median	All	0.279	0.695	.010	6	view →
GBM	DFS	Quartile	All	0.231	0.548	.021	3	view →
UCEC	DFS	Tertile	All	1.000	0.921	.045	2	view →
LUAD	OS	Median	II,III,IV	0.793	0.403	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ASB3–HNSC (DFS)

Open the HNSC breakdown →